A Letter to Our Shareholders from CEO Neil Kumar

Dear Shareholders, We are living in extraordinary times, marked by extraordinary human suffering. The COVID-19 pandemic is impacting all people and industries. We salute the brave physicians, nurses, first responders, and medical staff who are working across the globe to care for patients. In the face of these unprecedented challenges, we have been awed by […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., April 3, 2020 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on March 31, 2020, the compensation committee of BridgeBio’s board of directors granted six employees options to purchase an aggregate of 52,916 shares of the Company’s common stock with a per share […]